Pembrolizumab-Olaparib Combination Shows Promise in Delaying Ovarian Cancer Progression in Phase 3 Trial

A Phase 3 trial, ENGOT-OV43/GOG-3036/KEYLYNK-001, published in *Lancet Oncology*, suggests that a combination of chemotherapy with or without pembrolizumab, followed by maintenance pembrolizumab with or without olaparib, could be a potential first-line approach for patients with advanced BRCA non-mutated epithelial ovarian cancer. The investigators noted that while the combination could delay ovarian cancer progression, its increased toxicity remains an important consideration.